2-FEA

# Research Output: 2-FEA

**Substance:** 2-FEA (2-Fluoroethamphetamine; o-Fluoroethamphetamine)
**PSX ID:** PSX-0012
**Research Date:** 2026-05-07
**Readiness Assessment:** Sparse — emerging NPS with no substance-specific pharmacological studies published. All pharmacological claims below are based on structural analog inference and class-level data.

---

## Chemical Identity

**PubChem CID:** 20027466 (api_verified via get_pubchem_compound [Ref n/a — PubChem API])

| Property | Value | Source |
|---|---|---|
| IUPAC name | N-ethyl-1-(2-fluorophenyl)propan-2-amine | PubChem CID 20027466 |
| Molecular formula | C11H16FN | PubChem CID 20027466 |
| Molecular weight | 181.25 g/mol (freebase) | PubChem CID 20027466 |
| InChIKey | NIWYLNFSJJLYHU-UHFFFAOYSA-N | PubChem CID 20027466 |
| CAS number | 3871-89-4 (HCl salt) | Cayman Chemical Item 25266 [Ref 31] |
| SMILES (derived) | CCNC(C)Cc1ccccc1F | Structural derivation — not API-verified |
| Molecular weight (HCl salt) | ~217.7 g/mol | Web-retrieved [Ref 31] |

**⚠ FLAG — SMILES unverified:** The SMILES string CCNC(C)Cc1ccccc1F was derived from the IUPAC name and structural class; it was not returned by any API tool call. Generation agent should verify against PubChem CID 20027466 before publishing.

**Seed data discrepancy:** The brief lists no SMILES, molecular formula, or molecular weight. PubChem confirms C11H16FN and 181.25 g/mol — these can now be added to the database record.

### Structural Description
2-FEA is a synthetic substituted amphetamine. It belongs to the phenethylamine class, sharing the core 2-amino-1-phenylpropane skeleton of amphetamine. The molecule differs from amphetamine in two substitutions: (1) a fluorine atom at the ortho (2-) position of the phenyl ring, and (2) an ethyl group on the terminal amine nitrogen (N-ethyl substitution). It is the N-ethyl homolog of 2-fluoroamphetamine (2-FA), and the N-ethyl analog of 2-fluoromethamphetamine (2-FMA, which carries an N-methyl group instead). 2-FEA is also the 2-positional isomer of 3-fluoroethamphetamine (3-FEA), which has been physically seized and characterized in forensic cases (Yanini et al. 2018 [Ref 26]).

### Stereochemistry
2-FEA contains one chiral center at the alpha-carbon, making the molecule chiral. It is typically sold as a racemate (mixture of R and S enantiomers) on the research chemical market. No published data comparing the potency, pharmacokinetics, or receptor selectivity of the individual enantiomers of 2-FEA has been found. By structural analogy to amphetamine, the R(+) enantiomer may be more potent, but this is class-level inference only. The Hubner et al. 2022 [Ref 1] and 2024 [Ref 2] papers establish that chiral separation of NPS amphetamines including fluorinated phenyl derivatives is achievable via cyclodextrin CE and GC methods, enabling future enantiomeric studies.

### Physical Properties
- **Melting point:** Web sources report ~170–175°C for the HCl salt (web-retrieved; not from peer-reviewed primary source — ⚠ unverified)
- **Solubility, pKa, logP:** No published data found
- **Physical form:** Typically sold as white crystalline powder (HCl salt) per RC vendor descriptions

---

## Pharmacology

### Mechanism of Action

**⚠ FLAG — No substance-specific binding or release data published.** All mechanistic statements below are structural analog inferences. 2-FEA has not been the subject of any published in vitro binding, uptake inhibition, or release assay.

2-FEA is classified in the Psychedex database as a monoamine releasing agent selective for dopamine (DAT) and norepinephrine (NET). This classification is consistent with the broader amphetamine class pharmacology. Amphetamine-like NPS induce psychostimulation and euphoria primarily through NET and DAT inhibition and transporter-mediated (reverse-transport) release of NE and DA, displaying a catecholamine-selective profile (Simmler & Liechti 2018 [Ref 3]).

However, based on structure-activity relationship data for N-alkyl and ring-halogen substitutions, the serotonergic component of 2-FEA may be more significant than the seed data classification suggests:

1. **N-ethyl substitution augments SERT relative potency:** Fitzgerald et al. 2024 [Ref 6] demonstrated in rat brain synaptosome assays that increasing N-alkyl chain length (methyl → ethyl) augments relative potency at SERT in substituted amphetamines and cathinones, while also reducing releasing efficacy at NET and DAT. This suggests 2-FEA may have a higher SERT contribution relative to 2-FA and 2-FMA.

2. **Ortho-fluorination and serotonergic effects:** Rickli et al. 2015 [Ref 4] showed that para-fluorinated amphetamines (4-FA, 4-FMA) are more serotonergic than their non-fluorinated analogs. Whether this generalizes to the ortho (2-) position is not established in the literature.

3. **Community/market characterization:** PsychonautWiki [Ref 16] classifies 2-FEA as both a "Stimulant" and "Entactogen," implying recognized serotonergic activity. User reports describe it as less warm than 3-FEA but with some serotonergic character beyond pure catecholaminergic stimulants [Ref 17].

**⚠ FLAG — Pharmacological class discrepancy:** The seed data lists only DA and NE releasing activity. The SAR literature, community classification, and the PsychonautWiki entactogen label suggest serotonin release may also occur at some level. The generation agent should present this as inferred/uncertain, not established fact.

### Receptor Binding Affinity
No published Ki, EC50, or IC50 data for 2-FEA at any receptor or transporter. All values below are analog-derived estimates for context only.

Closest published analog data:
- **2-FA locomotor and discriminative stimulus:** 2-FA shows peak locomotor effects comparable to methamphetamine (5905–7758 counts at optimal dose), full substitution for methamphetamine in discriminative stimulus assays (ED50 0.32–0.71 mg/kg in rats), with rank-order locomotor potency placing 2-FA above 4-FMA but below 2-FMA and methamphetamine (Anchondo et al. 2025 [Ref 10]).
- **4-FA human DAT/NET profile:** 4-fluoroamphetamine at 100 mg (oral) produced strong BP elevation to 4–5 h and sustained tachycardia, with peak mood effects at 1 h post-dose; 150 mg arm was cancelled for safety (de Sousa Fernandes Perna et al. 2018 [Ref 11]).
- **N-ethyl substitution effect on DAT/SERT:** N-ethyl amphetamine derivatives consistently show augmented SERT relative to N-methyl analogs; combined N-ethyl with ring substitution reduces releasing efficacy at NET and DAT (Fitzgerald et al. 2024 [Ref 6]).

### Pharmacokinetics

**No published pharmacokinetic data for 2-FEA.** All PK estimates below are class-level inferences.

**Predicted metabolic pathways (analog inference from 2-FMA; Ishii et al. 2023 [Ref 27]):**
- **N-deethylation:** The primary N-dealkylation step would produce 2-fluoroamphetamine (2-FA) — analogous to how 2-FMA undergoes N-demethylation to 2-FA.
- **N-hydroxylation:** N-OH-2-FEA likely forms as a major metabolite, analogous to N-OH-2-FMA.
- **Beta-hydroxylation:** Aliphatic hydroxylation to produce a 2-fluoroephedrine-like product (diastereomers) is anticipated.
- **CYP enzyme involvement:** CYP2D6 is implicated for ring-substituted amphetamines; however, amphetamine itself shows minimal CYP2D6-mediated hepatic turnover (Law et al. 2022 [Ref n/a]), and the primary CYP contribution for 2-FEA is uncertain.

**Seed data cross-reference:** The seed data lists a tolerance half-life of 5 days and full reset at 1.5 weeks. No primary sources were found to confirm or refute these specific figures. They are consistent with the general pattern of dopaminergic stimulant tolerance for which a few days to weeks of abstinence is required, but the values should be flagged as unverified.

**Route of administration:** The seed data and PsychonautWiki [Ref 16] list insufflated as the primary and only documented ROA. Some vendor and blog sources describe oral administration (pellets, powder in capsule), but the seed database does not include oral dose/duration data. There is a note that oral duration may be substantially longer (4–6 h total) than the insufflated profile, based on standard bioavailability differences across amphetamine class compounds.

---

## History

### Discovery and Synthesis
No peer-reviewed publication establishing the date of first synthesis or institutional origin of 2-FEA has been identified. The compound belongs to the broad family of fluorinated amphetamine analogs that began appearing on the illicit drug market in the early 2000s (Ishii et al. 2023 [Ref 27] notes fluorinated amphetamine/methamphetamine analogs have been present since the early 2000s). 

2-FMA appeared on the online research chemical market as early as August 2007 (web-retrieved), and related compounds 2-FA and 4-FA were contemporaneous. A Bluelight user discussion thread from approximately 2015 [Ref 17] references 2-FEA as newly available from Swedish vendors, placing its market emergence no later than ~2015. The positional isomer 3-FEA was first characterized in seized material in 2018 (Yanini et al. 2018 [Ref 26]), suggesting the broader fluoroethamphetamine class was established on the NPS market by the mid-2010s.

### Regulatory History
- **Germany:** Controlled under the NpSG (Neue-psychoaktive-Stoffe-Gesetz / New Psychoactive Substances Act) effective November 26, 2016. Production, import for placement on market, administration to others, and trading are punishable; possession is illegal but not penalized.
- **United Kingdom:** Covered by the Psychoactive Substances Act 2016 (PSA 2016), which prohibits production, supply, importation, and exportation of psychoactive substances not otherwise exempted. Given its amphetamine-type structure, 2-FEA may additionally be classified as a Class A drug under the analogue provisions of the Misuse of Drugs Act 1971 (Al-Banaa et al. 2020 [Ref 28] provides context on PSA 2016 impact).
- **United States:** No specific federal scheduling of 2-FEA has been found. As a structural amphetamine analog, it may be subject to Schedule II treatment under the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption. Amphetamine itself is Schedule II.
- **Netherlands:** Web sources suggest 2-FEA is or was available legally in the Netherlands but subject to upcoming or recent NPS legislation (web-retrieved; unverified with primary legal source).
- **Canada:** The Controlled Drugs and Substances Act Schedule covers amphetamines and analogs; 2-FEA would likely be treated accordingly (not substance-specifically scheduled; no primary source confirmed).
- **Australia:** No specific scheduling found. The TGA Poisons Standard Schedule 9 covers analogues; 2-FEA likely falls under this.

**⚠ FLAG — Legal status:** No jurisdiction has been confirmed to have specifically and explicitly scheduled 2-FEA by name based on sources found in this research. All legal status information is either analogue-provision inference or web-retrieved, not confirmed via government database lookup or peer-reviewed legal analysis. This section requires editorial verification.

---

## Subjective Effects

No controlled human studies of 2-FEA have been conducted. All subjective effect information comes from community-sourced user reports and structural analog inference.

### Community-Reported Profile (user-report only)
From PsychonautWiki [Ref 16] and Bluelight [Ref 17]:
- **Stimulation and focus:** Described as classically stimulant in character, consistent with dopamine/norepinephrine release
- **Euphoria:** Reported; cognitive and physical
- **Entactogenic/serotonergic qualities:** PsychonautWiki classifies it as an entactogen in addition to stimulant; Bluelight users describe it as less "warm" than 3-FEA but with some social/empathic effects
- **Paradoxical combination:** Web sources report a paradoxical combination of sedating and stimulating effects, with serotonin release potentially accounting for the sedating component
- **Comparison to amphetamine:** Users describe it as "a lot like regular Amphetamine" [Ref 17]
- **Comparison to 2-FMA:** TripSit characterizes 2-FEA as closely related to 2-FMA and "presumably slightly less potent" [Ref 17]
- **Anxiety/paranoia:** Reported at high doses or after extended use/redosing
- **After-effects:** 1–3 hours of residual stimulation/fatigue described

### Analog-Supported Effect Profile
Based on 4-FA human trial data (de Sousa Fernandes Perna et al. 2018 [Ref 11]; Kuypers et al. 2018 [Ref 21]):
- Peak mood effects (vigor, friendliness, elation, arousal, positive mood) occur within the first 1–2 hours post-dose
- Attention and motor performance improvements during acute phase
- Negative affect (comedown) during the subacute phase (hours 5+)
- Drug liking and wanting elevated — indicative of abuse liability

### Dose Data (Insufflated — PsychonautWiki [Ref 16] — user-report only)
| Tier | Dose |
|---|---|
| Threshold | 15 mg |
| Light | 20–30 mg |
| Common | 30–40 mg |
| Strong | 40–60 mg |
| Heavy | 60+ mg |

**Note on seed data consistency:** The dose data in the brief matches PsychonautWiki exactly. These figures have not been validated in any controlled study and are based on community consensus.

### Duration Data (Insufflated — PsychonautWiki [Ref 16] — user-report only)
| Phase | Duration |
|---|---|
| Onset | 5–15 min |
| Come up | 5–10 min |
| Peak | 30–60 min |
| Offset | 30–60 min |
| After-effects | 1–3 hours |
| Total | 1–2.5 hours |

**Note on oral route:** Some web sources describe oral administration with a substantially longer total duration (4–6 hours) and later onset (30–60 min). The seed database only includes insufflated data. The generation agent should note that oral ROA data exists but is not captured in the current DB.

---

## Safety & Toxicity

### Overall Assessment
No published LD50 data, no published case reports of 2-FEA-specific overdose, and no controlled safety studies exist for 2-FEA. The exact toxic dosage is unknown (confirmed in seed data). All safety data is derived from structurally related fluorinated amphetamines.

### Class-Level Risk Framework (analog inference)

**Cardiovascular toxicity** is the primary acute safety concern for fluorinated amphetamines:
- 4-FA produces exaggerated blood pressure effects compared to MDMA and amphetamine, with documented cardiomyopathy, myocardial infarction, and cerebral hemorrhage in ED presentations (Gresnigt et al. 2022 [Ref 19])
- The 4-FA phase 1 human study cancelled the 150 mg arm after interim safety review due to severe blood pressure elevation (de Sousa Fernandes Perna et al. 2018 [Ref 11])
- Methamphetamine and amphetamine-type stimulants cause hypertension, accelerated atherosclerosis, vasospasm-induced acute coronary syndromes, sudden cardiac death, and dilated cardiomyopathy via excessive catecholamine release → vasoconstriction → tachycardia → endothelial dysfunction (Annawald et al. 2024 [Ref 32])

**Hyperthermia and BBB breakdown:**
- Stimulant-induced hyperthermia can progress to blood-brain barrier leakage → vasogenic edema → death, potentiated in warm environments and by physical exertion (Kiyatkin & Sharma 2019 [Ref 15])
- Docherty & Alsufyani 2021 [Ref 7]: MDMA-like stimulants cause life-threatening hyperthermia in rave/club environments; amphetamine-like NPS share cardiovascular sympathomimetic toxicity

**Neurotoxicity:**
- Para-halogenation of amphetamine increases mitochondrial toxicity and apoptosis in neuronal cells (SH-SY5Y) compared to non-halogenated analogs (Zhou et al. 2020 [Ref 20]). Whether this is relevant to ortho-fluorination (as in 2-FEA) is unknown.

**Abuse liability / locomotor:**
- 2-FA (the closest structural analog without the N-ethyl group) shows full substitution for methamphetamine in discriminative stimulus tests in rodents and locomotor effects comparable to methamphetamine; 2-FMA and other fluorinated analogs produce methamphetamine-like profiles (Anchondo et al. 2025 [Ref 10])
- 4-FA increases drug liking and wanting in humans, contributing to abuse liability (Kuypers et al. 2018 [Ref 21])

**Overdose clinical features (class-level; Spiller et al. 2013 [Ref 23]):**
- Mydriasis, tremor, agitation, hyperreflexia, combative behavior, confusion, hallucinations, delirium, anxiety, paranoia, movement disorders, seizures
- Management: benzodiazepines first-line for sympathomimetic syndrome; antipsychotics (ziprasidone, haloperidol) or dexmedetomidine as second-line

### Psychological Risks
- Amphetamine-class stimulants carry documented risks of anxiety, paranoia, psychosis, and mood disorders with chronic use
- Dependence formation: the seed data notes "moderately addictive with a high potential for abuse" — consistent with class-level data but unverified for 2-FEA specifically
- Drug liking and wanting (precursors to abuse) are elevated by fluoroamphetamines (Kuypers et al. 2018 [Ref 21])

---

## Harm Reduction

### General Principles (class-level; no 2-FEA-specific protocols published)

1. **Start low:** No human safety data exists for 2-FEA. The absence of controlled studies means individual variability in toxicity threshold is entirely unknown.
2. **Avoid warm/hot environments:** Stimulant-induced hyperthermia is potentiated by ambient temperature (Kiyatkin & Sharma 2019 [Ref 15]); avoid raves, saunas, or extended physical exertion while dosing.
3. **Cardiovascular monitoring:** Fluorinated amphetamines produce severe and sustained blood pressure elevation (de Sousa Fernandes Perna et al. 2018 [Ref 11]; Gresnigt et al. 2022 [Ref 19]). Individuals with pre-existing cardiovascular conditions face elevated risk.
4. **Avoid redosing:** Community reports note compulsive redosing; extended sessions increase cardiovascular and neurotoxicity risk.
5. **Drug interactions — critically avoid:** See Interactions section. Tramadol, MDMA, and cocaine combinations are all classified as lethal risk.
6. **Hydration:** Stimulants cause dehydration; controlled water intake is recommended, but overhydration (hyponatremia) is also a risk in hot environments.
7. **Testing:** Reagent tests (Marquis, Mecke, Simon's) can distinguish phenethylamines from other classes but cannot confirm specific compound identity. LC-MS/MS is required for definitive confirmation. Some RC vendors sell pellets containing mixed isomers (2/3-FEA), meaning the purchased substance may not be pure 2-FEA.
8. **Emergency response:** Standard sympathomimetic overdose protocol — benzodiazepines for agitation, cooling for hyperthermia, cardiac monitoring (Spiller et al. 2013 [Ref 23]). Emergency services should be alerted that the substance is a stimulant; report all co-administered drugs.

---

## Tolerance & Dependence

### Tolerance
No 2-FEA-specific data published. Seed data states: "Develops with prolonged and repeated use; tolerance half-life ~5 days; full reset ~1.5 weeks; cross-tolerance: dopamine, stimulant class."

These values are consistent with general stimulant tolerance dynamics but are not supported by any published primary source for 2-FEA specifically. Cross-tolerance with dopamine-releasing stimulants (amphetamine, methamphetamine, other fluoroamphetamines) is expected based on shared DAT/NET release mechanisms.

**⚠ FLAG:** Tolerance half-life (5 days) and full reset (1.5 weeks) not verified against any published source. These should be flagged as community-consensus values.

### Dependence
Seed data: Physical dependence moderate; psychological dependence moderate; moderately addictive with high abuse potential.

Analog data support:
- Fluorinated amphetamines produce drug liking and wanting comparable to classical stimulants (Kuypers et al. 2018 [Ref 21])
- 2-FA shows full methamphetamine-like abuse potential in rodent discriminative stimulus studies (Anchondo et al. 2025 [Ref 10])
- Dopamine-releasing agents have higher abuse liability than serotonin-releasing agents (Rothman & Baumann 2006 [Ref 29])
- The primarily catecholaminergic profile of 2-FEA predicts high abuse liability (Simmler & Liechti 2018 [Ref 3])

**⚠ FLAG:** Physical dependence classified as "moderate" in seed data. Classical amphetamines typically produce moderate-to-strong psychological dependence and variable physical dependence. Without 2-FEA-specific data, this rating is speculative.

### Withdrawal
No 2-FEA-specific withdrawal data. Class-level: amphetamine discontinuation typically produces fatigue, hypersomnia, depressed mood, increased appetite, and anhedonia. Duration and severity are dose- and frequency-dependent.

---

## Interactions

The seed data lists the following interactions. Below is the mechanistic analysis for each.

### Tramadol — Listed as Lethal ⚠
**Mechanism (published; Baldo 2018 [Ref 33]; Sheikholeslami et al. 2021 [Ref 13]):**
- Tramadol inhibits SERT and NET, causing serotonin accumulation in the synapse
- 2-FEA (as a monoamine releaser) increases serotonin, dopamine, and norepinephrine in the synapse via reverse transport
- Combined serotonergic excess from both mechanisms creates conditions for serotonin toxicity syndrome (hyperthermia, rigidity, myoclonus, seizures → death)
- Additionally, tramadol is metabolized by CYP2D6 and CYP3A4; if 2-FEA or co-administered MDMA inhibits CYP2D6, tramadol levels may rise unpredictably
- This interaction is pharmacodynamic (additive serotonin toxicity) + potentially pharmacokinetic (CYP inhibition)
- **Assessment: Confirmed lethal class-level mechanism; label as lethal is appropriate**

### MDMA — Listed as Lethal ⚠
**Mechanism (published; de la Torre et al. 2004 [Ref 34]; Papaseit et al. 2020 [Ref 14]; Pilgrim et al. 2012 [Ref 24]):**
- MDMA is a potent releaser of serotonin (primarily), dopamine, and norepinephrine
- Combined with 2-FEA (which releases dopamine, norepinephrine, and possibly serotonin), both substances compete for the same monoamine transporters in reverse-transport mode
- The combination produces additive/synergistic monoamine excess → serotonin syndrome risk, extreme hyperthermia, cardiovascular collapse
- MDMA also inhibits CYP2D6 via mechanism-based inhibition, which may reduce metabolism of co-administered drugs including 2-FEA
- Pilgrim et al. 2012 [Ref 24] documents fatal serotonin toxicity from MDMA+MAOI combinations with identical clinical picture
- **Assessment: Confirmed lethal class-level mechanism; label as lethal is appropriate**

### Cocaine — Listed as Lethal ⚠
**Mechanism (published; Docherty & Alsufyani 2021 [Ref 7]):**
- Cocaine is a monoamine reuptake inhibitor (blocks DAT, NET, SERT)
- 2-FEA is a monoamine releaser (reverse-transports DA and NE out via DAT and NET)
- Combination of a DAT/NET blocker with a DAT/NET releaser creates massive, unsustainable increases in extracellular dopamine and norepinephrine
- Consequences include severe tachycardia, hypertension, vasoconstriction, hyperthermia, and potentially fatal cardiac arrhythmia or myocardial infarction
- Additionally, cardiovascular synergy: both substances produce sympathomimetic effects that are additive
- **Assessment: Plausible lethal class-level mechanism; label as lethal is consistent with stimulant+stimulant harm reduction guidance. No 2-FEA+cocaine-specific case reports found.**

### Alcohol — Listed as Unknown ⚠
**Mechanism:** Ethanol and amphetamine-type stimulants interact in complex ways: ethanol may increase plasma amphetamine concentrations by presystemic (first-pass) effects (Schoretsanitis et al. 2019 [Ref n/a]), blunt subjective intoxication leading to overconsumption, and increase cardiovascular strain. The combination is considered dangerous but not uniformly lethal in the literature. Specific interaction data for 2-FEA does not exist.
- **Assessment: Classification as "unknown" is appropriate given absence of 2-FEA-specific data. The interaction should be listed as potentially dangerous, not lethal.**

### Additional Interaction Considerations (not in seed data)
- **MAO inhibitors (MAOIs):** Combination of a monoamine releasing agent with any MAOI is potentially lethal via hypertensive crisis and/or serotonin syndrome. Amphetamine derivatives show MAO inhibitory activity themselves at higher concentrations (Reyes-Parada et al. 2019 [Ref 12]).
- **Antidepressants (SSRIs, SNRIs):** Pharmacodynamic interaction via additive serotonin load; increased serotonin syndrome risk (Inan et al. 2020 [Ref 22]).
- **CYP2D6 inhibitors:** May raise 2-FEA blood levels by reducing N-deethylation, as CYP2D6 is implicated in amphetamine metabolism.

---

## Legal Status

| Jurisdiction | Status | Mechanism | Confidence |
|---|---|---|---|
| United Kingdom | Illegal (production/supply) | Psychoactive Substances Act 2016 [Ref 28]; likely also MDA 1971 analogue clause (Class A) | High (PSA 2016 is broad) |
| Germany | Controlled — NpSG | New Psychoactive Substances Act, effective 2016-11-26 | High (web-retrieved, specific to amphetamine-type NPS) |
| United States | Potentially Schedule II | Federal Analogue Act (21 U.S.C. §813) if intended for human consumption | Moderate (no substance-specific scheduling found) |
| Netherlands | Uncertain (possibly covered by NPS law) | NPS legislation; web-retrieved | Low |
| Canada | Likely covered | CDSA analogue provisions | Low (no substance-specific scheduling found) |
| Australia | Likely Schedule 9 | TGA Poisons Standard NPS analogue provisions | Low |
| Sweden | Likely covered | Narcotics Act analogue provisions | Moderate (Swedish vendors historically sold 2-FEA; regulatory response expected) |

**⚠ FLAG:** No primary government legal source (official schedule, statutory instrument, or government database entry) was retrieved that names 2-FEA specifically in any jurisdiction. All legal status information is inferred from analogue provisions. Generation agent should present this with appropriate uncertainty.

---

## Clinical Trials

No clinical trials involving 2-FEA were found on ClinicalTrials.gov or in any published literature. No trials are anticipated for this compound given its NPS legal status in most jurisdictions.

---

## Community Feedback Analysis

**No community feedback was submitted** (Part A2 of the brief was empty).

---

## Gaps & Flags

The following items require editorial attention before article publication:

### Safety-Critical Gaps
1. **⚠ No published LD50 or toxic dose data** for 2-FEA in any species. Exact toxic dosage is unknown. All safety thresholds are derived from analog inference.
2. **⚠ No published case reports** of 2-FEA overdose, adverse events, or death. Cannot confirm whether lethal interaction classifications (tramadol, MDMA, cocaine) are based on documented 2-FEA cases or class-level inference — they appear to be class-level.
3. **⚠ Tolerance and dependence values** (half-life 5 days, full reset 1.5 weeks, physical/psychological moderate) in seed data are unverified against any published primary source.

### Pharmacological Gaps
4. **⚠ No binding affinity data** (Ki/EC50/IC50) at DAT, NET, SERT, or any other target for 2-FEA. All receptor pharmacology is structural analog inference.
5. **⚠ Serotonin releasing potential uncertain:** The seed data classifies 2-FEA as DA+NE releasing only. However, N-ethyl substitution SAR data (Fitzgerald et al. 2024 [Ref 6]) suggests augmented SERT activity relative to N-methyl analogs. PsychonautWiki classifies 2-FEA as an entactogen (implying serotonin involvement). This is a meaningful discrepancy — the generation agent should present serotonin release as uncertain/possible rather than confirmed or denied.
6. **⚠ No published pharmacokinetic data** (half-life, Tmax, bioavailability, volume of distribution) for 2-FEA. Metabolic pathways are predicted by analogy to 2-FMA.
7. **⚠ No enantiomeric potency data** for 2-FEA. The RC market product is expected to be racemic.

### Chemical Data Gaps
8. **⚠ SMILES unverified:** The SMILES string (CCNC(C)Cc1ccccc1F) was structurally derived, not retrieved by API. Verify against PubChem CID 20027466 before publishing.
9. **⚠ No SMILES in PubChem API response:** The PubChem tool call did not return a SMILES string — this should be retrieved via PubChem REST API directly.

### Legal Status Gaps
10. **⚠ No primary legal sources verified** for 2-FEA scheduling in any jurisdiction. Legal status section is analog-provision inference throughout.

### Structural Data Points Absent from Seed
11. The seed data lacks: Molecular formula (C11H16FN), Molecular weight (181.25 g/mol), InChIKey (NIWYLNFSJJLYHU-UHFFFAOYSA-N), and CAS number (3871-89-4 for HCl salt). These are now confirmed and should be added to the DB record.

### Oral Route Gap
12. The seed database only captures insufflated dosing and duration. Some sources describe 2-FEA oral administration with substantially different duration (4–6 hours total, 30–60 min onset). If oral use is common, the DB should include oral dose/duration data.

---

## Research Summary

2-FEA (2-Fluoroethamphetamine) is an emerging research chemical stimulant with very limited published literature. It is a structural substituted amphetamine — the N-ethyl homolog of 2-FA and N-ethyl analog of 2-FMA — with a fluorine atom at the ortho-position of the phenyl ring. No substance-specific pharmacological, pharmacokinetic, toxicological, or clinical studies have been published. Chemical identity has been confirmed via PubChem (CID 20027466). The compound appeared on RC markets approximately 2014–2016. All pharmacological characterization is based on structural analog inference from related fluorinated amphetamines and N-substituted phenethylamines.

The most relevant analog data comes from:
- **Anchondo et al. 2025** [Ref 10]: 2-FA shows methamphetamine-comparable locomotor and discriminative stimulus effects in rodents, with potential adverse effects including heart failure, cerebral hemorrhage, and death.
- **de Sousa Fernandes Perna et al. 2018** [Ref 11]: 4-FA human trial showing severe BP elevation warranting cancellation of the 150 mg arm; drug liking/wanting elevated (Kuypers et al. 2018 [Ref 21]).
- **Fitzgerald et al. 2024** [Ref 6]: N-ethyl substitution augments SERT relative potency and modifies DAT/NET releasing efficacy.
- **Ishii et al. 2023** [Ref 27]: 2-FMA metabolic pathways (N-deethylation to 2-FA, N-hydroxylation, beta-hydroxylation) predicted to apply to 2-FEA.